Xilio Therapeutics, Inc. Stock Price, News & Analysis

Xilio Therapeutics (NASDAQ: XLO) reported late-breaking Phase 2 data for vilastobart plus atezolizumab at SITC on Nov 7, 2025 showing a 40% objective response rate (ORR) in heavily pre-treated patients with MSS metastatic colorectal cancer (mCRC) who had no liver metastases and high plasma TMB (≥10 mut/Mb).

Data cutoff was May 12, 2025: 44 patients treated (100 mg Q6W vilastobart + 1200 mg Q3W atezolizumab), 27 without liver metastases, 24 evaluable for plasma TMB. Company estimates ~55% of non‑MSI‑H CRC are plasma TMB‑high. Responses included tumor reductions up to 71%. Safety: mostly Grade 1–2, 5% discontinued for treatment‑related AEs and 7% experienced colitis. Xilio will host a conference call/webcast on Nov 10, 2025 at 4:30 p.m. ET.

Xilio Therapeutics (NASDAQ: XLO) presented preclinical and clinical data at SITC 2025 highlighting its masked immunotherapy platform and clinical-stage programs efarindodekin alfa (tumor-activated IL-12) and vilastobart (tumor-activated, Fc-enhanced anti-CTLA-4).

Key clinical facts: as of Sept 2, 2025 62 patients received efarindodekin alfa in Phase 1 dose escalation; doses exceeded recombinant IL-12 by >100-fold; two partial responses observed (confirmed PR: 33% reduction; unconfirmed PR: 55% reduction). Vilastobart Phase 2 ctDNA data (cutoff May 12, 2025) showed ≥75% ctDNA reductions correlated with radiographic response in 23 evaluable MSS mCRC patients without liver metastases.

Xilio Therapeutics (Nasdaq: XLO) granted a non-qualified stock option to purchase 5,700 shares to a new employee effective November 1, 2025, under its 2022 Inducement Stock Incentive Plan. The exercise price is $0.7967 per share, equal to the closing price on October 31, 2025. Each option has a 10-year term.

Vesting: 25% vests on the first anniversary of employment, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service and plan/option agreement terms. The grant was made under Nasdaq Listing Rule 5635(c)(4).

Xilio Therapeutics (Nasdaq: XLO) will present late-breaking Phase 2 data for vilastobart (tumor-activated, Fc-enhanced anti-CTLA-4) at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, Nov 5–9, 2025, National Harbor, Maryland.

The poster (Late-Breaking Abstract No. 1315) reports response rates for vilastobart combined with atezolizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer enriched for high plasma tumor mutational burden (pTMB). Presentation: Friday, Nov 7, 2025; Poster Hall hours 9:00 a.m.–7:00 p.m. EST; Prince George ABC Exhibit Halls, Gaylord National Resort.

The poster will be posted on Nov 7, 2025 in the company’s "Our Approach—Presentations & Publications" section at www.xiliotx.com.

Xilio Therapeutics (Nasdaq: XLO) announced multiple poster presentations at the SITC 40th Annual Meeting, Nov 6-9, 2025, Gaylord National Convention Center, National Harbor, MD.

Xilio will present clinical data for vilastobart (anti-CTLA-4) and XTX301 (efarindodekin alfa) (tumor-activated IL-12), plus preclinical data on masked T cell engager programs. Key posters: ctDNA as a surrogate biomarker for vilastobart + atezolizumab in MSS mCRC (Abstract 541) and XTX301 Phase 1 IL-12 pharmacodynamic data (Abstract 567) — both presented Friday, Nov 7, 2025, poster hall 9:00 a.m.–7:00 p.m. EST (Gaylord Exhibit Halls A & B1). Masked T cell engager poster (Abstract 972) presented Saturday, Nov 8, 2025, poster hall 9:00 a.m.–8:40 p.m. EST.

Xilio Therapeutics (Nasdaq: XLO) announced on Oct 2, 2025 that effective Oct 1, 2025 it granted non‑qualified stock options to purchase 26,000 shares to three new employees under its 2022 Inducement Stock Incentive Plan.

The options have an exercise price of $0.8326 (equal to the closing price on Oct 1, 2025), a 10‑year term, and vest 25% after 1 year with the remaining 75% vesting in 36 equal monthly installments, subject to continued service. Grants were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4) and are subject to the plan and option agreement terms.

Xilio Therapeutics (NASDAQ:XLO) has initiated Phase 2 patient dosing for efarindodekin alfa (XTX301), a tumor-activated IL-12 therapy for advanced solid tumors. The company has also achieved a $17.5 million development milestone under its exclusive license agreement with Gilead Sciences.

Phase 1 data showed promising results with two partial responses in late-line patients and a generally well-tolerated safety profile. The company has selected the recommended Phase 2 dose (RP2D) based on these encouraging results. The therapy demonstrated sustained interferon gamma signaling without tachyphylaxis throughout treatment cycles.

Financially, Xilio reported cash and cash equivalents of $121.6 million as of June 30, 2025. With the additional milestone payment, the company expects to fund operations into Q1 2027.

Xilio Therapeutics (NASDAQ:XLO) reported Q2 2025 financial results and pipeline updates. The company's lead candidate vilastobart showed promising Phase 2 data with a 26% objective response rate in metastatic MSS colorectal cancer patients without liver metastases. The therapy demonstrated deep, durable responses and a differentiated safety profile.

Financial highlights include $121.6 million in cash and cash equivalents, a net loss of $15.8 million, and revenue of $8.1 million. The company completed a follow-on offering raising $50.0 million in initial gross proceeds, with potential for additional $100.0 million from warrant exercises.

Xilio expects to nominate development candidates for its masked T cell engager programs in H2 2025 and projects cash runway through Q3 2026.

Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted inducement stock options to two new employees. The grants include options to purchase 134,000 shares of common stock at an exercise price of $0.65 per share, matching the closing price on August 1, 2025.

The stock options have a ten-year term with a vesting schedule of 25% after the first year and the remaining 75% vesting in 36 monthly installments. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).